Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGIV-C for myasthenia gravis exacerbations
2013-005098-28Phase 3Completed
- Sponsor
- Grifols
- Start
- Oct 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gamunex in myasthenia gravis (MG), sponsored by Grifols. Primary endpoint: Change in QMG score from baseline to Day 14. Started Oct 2014; status: completed.
02
Drugs
gamunex
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2013-005098-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005098-28.